Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 944-968-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Repeat Oral Dose Toxicity
A dog subchronic (13 weeks; gavage; mixture of N,N-dimethyldecanamide and N,N-dimethyloctanamide) gave a systemic NOAEL of 200mg/kg bw/d, and a local NOEL of 40mg/kg bw/d. Furthermore, no adverse toxicological effects were noted following histpathological examinations. It may be predicted from this that (analogue read-across) the registered substance, Reaction mass of N,N-dimethyldodecanamide and N,N-dimethyltetradecanamide, would share a similar toxicity profile.
Dermal: No data available
Inhaltive: No reliable relevant studies available.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2000
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study according to OECD guideline under GLP
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 409 (Repeated Dose 90-Day Oral Toxicity Study in Non-Rodents)
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- dog
- Strain:
- Beagle
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Winkelmann, Borchen, Germany
- Age at study initiation: 19-22 weeks old (at week -1)
- Weight at study initiation: between 6.4-9.0 kg (at week -1)
- Housing:individual cages
- Diet (e.g. ad libitum): ad libitum, ssniff HH complete food for dogs, 12 mm pellets from ssniff Versuchstierdiaten GmbH, Soest, Germany
- Water (e.g. ad libitum): ad libitum, common drinking water quality
- Acclimation period: 17 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21.0 - 23.5°C
- Humidity (%): 25-50%
- Air changes (per hr): forced ventilated room
- Photoperiod (hrs dark / hrs light): Premises illuminated by diffuse daylight, but mainly fluorescents lamps with regulated
the day/night cycle (12h each)
- Cleaning: spray cleaned each afternoon (hot water) - Route of administration:
- oral: gavage
- Vehicle:
- other: applied as 0.5% aqueous tylose suspension
- Details on oral exposure:
- According to guideline
PREPARATION OF DOSING SOLUTIONS:
- suspensions were prepared weekly
- stability ensured for 8 days in range of concetrations used
- Analytical content check of the formulation performed during the course of the study
ADMINISTRATION:
Administration via gavage: Administration volumen: 10ml, Application once daily 2 hours before feeding in the morning
VEHICLE
- Justification for use and choice of vehicle (if other than water): common vehicle
- Concentration in vehicle: 4.0 mg/ml, 20.0 mg/ml and 50.0mg/ml
- Amount of vehicle (if gavage):
- Lot/batch no. (if required):
- Purity: - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analytical verification of concentration in vehicle via GC, reported recovery >97%
- Duration of treatment / exposure:
- 13weeks
- Frequency of treatment:
- once daily 2 hours before feeding in the morning
- Dose / conc.:
- 40 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 200 mg/kg bw/day (actual dose received)
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- From the second day of the study onwards, dose reduced to 800 mg/kg and from the 4th day to 500 mg/kg due to reduced health of animals
- No. of animals per sex per dose:
- 4 male and 4 female per dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- according to guideline
- Positive control:
- not necessary
- Observations and examinations performed and frequency:
- According to guideline
- Sacrifice and pathology:
- According to guideline
- Statistics:
- In line with the small number of animals per group, a descriptive statistical evaluation was performed
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- effects observed, treatment-related
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- - General findings
reflexes, body temperatures, pulse rates, blood pressure and heart rates as well as electrocardiograms did not
yield relevant changes up to and including group III
- Clinical observations
nutritional state were not relevant changed
From group II upwards, vomiting and salivation were observed repeatedly, effects in group III consisted of uncoordinated
movements, nasal discharge, lateral/prone position, and trembling
-mortality
one animal of group III had to be sacrificed on day 3 (showing lateral position)
another animal of group III died in week 7 of the study exhibiting lateral position, bloody nasal and oral discharge
before death
- Feed and water intake
no notable differences could be detected in feed intake between control animals and animals up to and including group III
no descriptions of unusual findings in water intake in the observation records up to and including group III
- Ophthalmoscopic findings
no ocular changes were detected up to and including group II. In group III, a cataractous lens occurred in the right eye of one animal
- Body weights
The mean body weight gain of males and females showed no changes up to and including group III in comparison to the control group
- Haematoloqy
no changes were observed up to and including group III
- Clinical chemistry
APh increased in two animals (group III)
N-Dem: increased in all females of group II and marginally increased in one animal, all animals group III
P 450: increased in two animals (group III)
In all the other clinico-chemical parameters determined no changes were detected up to and including group III
- Urines
no appreciabledifferences were detected between the controls and the animals in the treatment groups up to and including group III
- Gross-pathological and histopathological findings
necropsy and histopathological examination did not reveal toxicologically relevant effects up to and including group III
- Gravimetric organ findings
there was an increase in absolute and relative liver weights in males of group III - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 40 - < 200 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: repeated vomiting and salivation, increased N-Demethylase values; for group III (500-1000mg/kg bw) uncoordinated movements, nasal discharge, lateral/prone position, and trembling, death
- Key result
- Dose descriptor:
- LOEL
- Effect level:
- >= 200 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: repeated vomiting and salivation, increased N-Demethylase values; for group III (500-1000mg/kg bw) uncoordinated movements, nasal discharge, lateral/prone position, and trembling, death
- Critical effects observed:
- not specified
- Conclusions:
- As there were only local effects and slightly increased N-DEM values in the absence of any other finding the NOAEL is established at 200 mg/kg bw/d
- Executive summary:
To assess the subchronic toxicity of the test substance subchronic test according toOECD Guideline for Testing of Chemicals No. 409 "Subchronic Oral Toxicity - Non rodent", adopted 12th of May 1981 was performed.
Therefore Groups of 4 male and 4 female beagle dogs per dosage were treated once daily by gavage over a period of 13 weeks with following daily oral doses:
Control group: 0 mg/kg b.w.
Group I : 40 mg/kg b.w. of the test substance
Group II : 200 mg/kg b.w. of the test substance
Group III : 1000 mg/kg b.w. of the test substance
From the second day of the study onwards, 1000 mg/kg were reduced to 800 mg/kg, and from the 4th day of the study onwards, 800 mg/kg were reduced to 500 mg/kg due to a markedly reduced health status of some group III-animals.
The official result in the report was:
Tests of the reflexes, body temperatures, pulse rates, blood pressure, and heart rates showed no changes up to and including group III. The same holds true for the electrocardiograms . The nutritional state, feed intake, and body weight gain also yielded no adverse effects up to and including group III. Clinical observations evidenced repeated vomiting and salivation from group II upwards. Additional effects in group III consisted of uncoordinated movements, nasal discharge, lateral/prone position, and trembling. All these effects from group II upwards are considered to be due to treatment with the test compound. Animal no. B 915/group III had to be sacrificed on day 3 of the study showing lateral position, flat breathing, and bloody faeces before sacrificing, and animal no. B 944/group III died in week 7 of the study exhibiting lateral position, bloody nasal and oral discharge before death. Due to the lung findings observed in the histopathological investigations, these two events might be associated with an unintentional intratracheal application.
Ophthalmoscopy showed a lens cataract in one animal of group III. This effect is seen to be treatment-related. Haematology and Differential blood counting showed no changes up to and including group III. Clinical chemistry evidenced a substance-related elevation of APh-values in group III. Increased N-Demethylase values from group II upwards and increased Cytochrome P450-values in group III are seen as treatment-related effects giving evidence for an increased metabolic activity in the liver. In this context the increased liver weights in males of group III are also considered to be treatment-related. Urinalyses showed no changes up to and including group III. Necropsy and histopathological examination did not reveal toxicologically relevant effects up to and including group III. Besides increased liver weights in males of group III (see above), no changes in organ weights were detected up to and including group III.
The author followed that based on the reported effects it can be concluded that 40 mg/kg Test substance administered orally by gavage to beagle dogs daily over a period of 13 weeks were tolerated without adverse effects.
In contrast to this conclusion the applicant assessed to effects observed as follow:
The NOEL at 40 mg/kg bw/d (0.4%) reported is based on local effects caused by oral application of the test substance at irritating concentrations (≥2%). At 200 mg/kg bw/d clinical chemistry revealed only slightly increased N-DEM values in the absence of any other finding. The increase of this parameter is an indication for a minimal liver enzyme induction but not for an adverse effect.Therefore the NOAEL is established at 200 mg/kg bw/d
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Justification for type of information:
- 1. HYPOTHESIS FOR THE ANALOGUE APPROACH
The read-across hypothesis proposed is that the organism is not exposed to common compounds but rather, as a result of structural similarity, that different compounds have similar toxicological and fate properties. In this case the ECHA Read-Across Assessment Framework (RAAF) Scenario 2 is used.
2. SOURCE AND TARGET CHEMICAL(S) (INCLUDING INFORMATION ON PURITY AND IMPURITIES)
Source: N,N-Dimethyldecan-1-amide, mixture with N,N-Dimethyloctanc-1-amide [CAS 67359-57-3]
Target: Reaction Mass of N,N-Dimethyldodecanamide and N,N-Dimethyltetradecanamide [EC not assigned; CAS not assigned]
3. ANALOGUE APPROACH JUSTIFICATION
It may be concluded that both the registered substance (target) and the source molecules can be regarded as close structural analogues having both similar physical chemical and toxicological properties. It follows that where endpoints for the registered substance may not have experimental evidence, particularly those involving animal studies, that these can be addressed by read across grouping using an analogue approach. It is therefore proposed that, after careful assessment, experimental data from the source molecules may be used as surrogate evidence for read across to the registered substance. Please refer to attached document for information on the data available to support the read-across.
4. DATA MATRIX
Please refer to attached document - Reason / purpose for cross-reference:
- read-across source
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- >= 40 - < 200 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: repeated vomiting and salivation, increased N-Demethylase values; for group III (500-1000mg/kg bw) uncoordinated movements, nasal discharge, lateral/prone position, and trembling, death
- Key result
- Dose descriptor:
- LOAEL
- Effect level:
- >= 200 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: repeated vomiting and salivation, increased N-Demethylase values; for group III (500-1000mg/kg bw) uncoordinated movements, nasal discharge, lateral/prone position, and trembling, death
- Critical effects observed:
- not specified
Referenceopen allclose all
An unintentional intratracheal application might have been the cause for the effects in the lungs (severe bronchopneumonia in no. B 915/group III and acute edema in no. B 944/group III) leading to premature sacrificing or death of these two animals.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- NOAEL
- 200 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- dog
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
No study investigating the repeated dose toxicity of Reaction mass of N,N-dimethyldodecanamide and N,N-dimethyltetradecanamide is available. Data are available for an analogue of the substance - mixture of N,N-dimethyldecanamide and N,N-dimethyloctanamide. These data are read across to the registered substance based on the close similarity in chain length and toxicological behaviour.
Oral:
To assess the subchronic toxicity of a N,N-dimethylamide mixture a subchronic dog study according to OECD Guideline No. 409 was performed (Bayer 2000, J. Ruf). Therefore Groups of 4 male and 4 female beagle dogs per dosage were treated once daily by gavage over a period of 13 weeks with following daily oral doses: 0 mg/kg bw; Group I : 40 mg/kg bw; Group II : 200 mg/kg bw; Group III : 1000 mg/kg bw From the second day of the study onwards, 1000 mg/kg were reduced to 800 mg/kg, and from the 4th day of the study onwards, 800 mg/kg were reduced to 500 mg/kg due to a markedly reduced health status of some group III-animals. The following result was given in the official report: “Tests of the reflexes, body temperatures, pulse rates, blood pressure, and heart rates showed no changes up to and including group III. The same holds true for the electrocardiograms . The nutritional state, feed intake, and body weight gain also yielded no adverse effects up to and including group III. Clinical observations evidenced repeated vomiting and salivation from group II upwards. Additional effects in group III consisted of uncoordinated movements, nasal discharge, lateral/prone position, and trembling. All these effects from group II upwards are considered to be due to treatment with the test compound. Animal no. B 915/group III had to be sacrificed on day 3 of the study showing lateral position, flat breathing, and bloody faeces before sacrificing, and animal no. B 944/group III died in week 7 of the study exhibiting lateral position, bloody nasal and oral discharge before death. Due to the lung findings observed in the histopathological investigations, these two events might be associated with an unintentional intratracheal application. Ophthalmoscopy showed a lens cataract in one animal of group III. This effect is seen to be treatment-related. Haematology and Differential blood counting showed no changes up to and including group III. Clinical chemistry evidenced a substance-related elevation of APh-values in group III. Increased N-Demethylase values from group II upwards and increased Cytochrome P450-values in group III are seen as treatment-related effects giving evidence for an increased metabolic activity in the liver. In this context the increased liver weights in males of group III are also considered to be treatment-related. Urinalyses showed no changes up to and including group III. Necropsy and histopathological examination did not reveal toxicologically relevant effects up to and including group III. Besides increased liver weights in males of group III (see above), no changes in organ weights were detected up to and including group III.” The author followed that based on the reported effects it can be concluded that 40 mg/kg test substance administered orally by gavages to beagle dogs daily over a period of 13 weeks were tolerated without adverse effects.
In contrast to this conclusion the applicant assessed the effects observed as follow: The NOEL at 40 mg/kg bw/d (0.4%) reported is based on local effects caused by oral application of the test substance at irritating concentrations (≥2%). At 200 mg/kg bw/d clinical chemistry revealed only slightly increased N-DEM values in the absence of any other finding. The increase of this parameter is an indication for a minimal liver enzyme induction but not for an adverse effect. Therefore the NOAEL (systemic) is established at 200 mg/kg bw/d.
Dermal:
No data available.
Inhalative:
No relevant reliable data available.
Justification for classification or non-classification
There are currently no data available leading to a classification of N,N-dimethyldecanamide for its repeated oral or inhalation toxicity.
According to GHS (Regulation (EU) 1272/2008) the following criteria must be fullfilled:"3.9.2.1. Substances are classified as specific target organ toxicants...... 3.9.2.9.6. Thus classification in Category 1 is applicable, when significant toxic effects observed in a 90-day repeated dose study conducted in experimental animals are seen to occur at or below the guidance values (C).....
Category 1 classification: oral: C ≤ 10 mg/kg body weight/day
Category 2 classification: oral: 10 < C ≤ 100 mg/kg body weight/day
According to EU-criteria DSD (67/548/EEC) the following criteria must be fulfilled for the classification R48 Danger of serious damage to health by prolonged exposure “... Substances and preparations are classified at least as harmful when these effects are observed at levels of the order of (guide values): oral, rat ≤ 50 mg/kg body weight/day..."
As the lowest determined oral NOAEL (systemic) was higher than 100mg/kg body weight/day and lower values only led to local effect the substance has not to be classified derived for the oral repeated dose studies.
It may be predicted from this that (analogue read-across) Ninol CAA would share a similar toxicity profile.
Labelling repeated dose toxicity:
GHS: no classification
DSD: no classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.